Vigilant Capital Management adds Alnylam Pharmaceuticals (ALNY) to its portfolio

Alnylam Pharmaceuticals (ALNY) : Vigilant Capital Management added new position in Alnylam Pharmaceuticals during the most recent quarter end. The investment management firm now holds 100 shares of Alnylam Pharmaceuticals which is valued at $3,532 , the company said in a statement filed on Oct 14, 2016 with the SEC.

Other Hedge Funds, Including , Fox Run Management L.l.c. added ALNY to its portfolio by purchasing 7,700 company shares during the most recent quarter which is valued at $268,191. Alnylam Pharmaceuticals makes up approx 0.16% of Fox Run Management L.l.c.’s portfolio.Legal General Group Plc reduced its stake in ALNY by selling 4,030 shares or 1.36% in the most recent quarter. The Hedge Fund company now holds 292,912 shares of ALNY which is valued at $10,202,125. Alnylam Pharmaceuticals makes up approx 0.01% of Legal General Group Plc’s portfolio.Creative Planning boosted its stake in ALNY in the latest quarter, The investment management firm added 542 additional shares and now holds a total of 612 shares of Alnylam Pharmaceuticals which is valued at $21,316.Bnp Paribas Arbitrage Sa reduced its stake in ALNY by selling 586 shares or 5.27% in the most recent quarter. The Hedge Fund company now holds 10,540 shares of ALNY which is valued at $740,962.

Alnylam Pharmaceuticals closed down -0.85 points or -2.35% at $35.32 with 20,10,809 shares getting traded on Friday. Post opening the session at $36.3, the shares hit an intraday low of $35.24 and an intraday high of $36.49 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Alnylam Pharmaceuticals reported $-1.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.22 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.27. The company had revenue of $8.70 million for the quarter, compared to analysts expectations of $7.98 million. The company’s revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.85 EPS.

Many Wall Street Analysts have commented on Alnylam Pharmaceuticals. Alnylam Pharmaceuticals was Downgraded by Morgan Stanley to ” Equal-Weight” on Oct 7, 2016. Alnylam Pharmaceuticals was Initiated by Morgan Stanley to “Overweight” on Aug 2, 2016.

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Company’s pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease with a pipeline of RNAi therapeutics toward genetically validated liver-expressed disease in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-GO1 ALN-TMP ALN-PCS ALN-PCSsc ALN-AC3 ALN-ANG ANGPTL3 ALN-HBV ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Leave a Reply

Alnylam Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Alnylam Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.